N/A N=153 Treatment for Adolescent Marijuana Abuse
Marijuana Abuse
Primary: Marijuana Abstinence (2 Weeks or Greater) — 72.5; 68.6; 45.1 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=70 Treatment for Cannabis Withdrawal and Dependence
Cannabis Dependence
Primary: Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 8 — -334.21; -359.95 ng/mg
Phase 4 N=175 Buspirone Treatment for Marijuana Dependence
Marijuana Dependence
Primary: Percent Marijuana-negative Urine Drug Screens (UDS) — 7.2; 6.4 percentage of UDS
Phase 2 N=21 Pregnenolone and Marijuana Dependence
Marijuana Dependence
Primary: Subjective Rating of Marijuana Craving on 1-7 Likert Scale — 1.64; 0.80 units on a scale
Phase 2 N=76 Vilazodone Treatment for Marijuana Dependence
Marijuana Dependence
Primary: Percent Marijuana-negative Urine Drug Screens (UDS) — 5.5; 3.6 percentage of UDS
Phase 3 N=52 Nabilone for Cannabis Dependence: A Pilot Study
Cannabis Dependence · Marijuana Dependence
Primary: Change From Baseline in Cannabis Use at 10 Weeks — 268.8; 286.7; 490.3; 216.9 Ratio
Phase 2 N=15 Study of Quetiapine Treatment for Cannabis Dependence
Cannabis Dependence
Primary: Maximum Tolerated Dose of Quetiapine — 197 milligrams
Phase 2 N=24 The Effect of Prescription Medications in Marijuana Users
Marijuana Abuse
Primary: Peak Effect of Marijuana Withdrawal — 4.6; 4.1; 2.9; 1.7 units on a scale
Phase 2 N=66 Clinical and Neurobiological Effects of Cannabis Dependence in Young Adults
Cannabis Dependence · Cannabis Withdrawal
Primary: Withdrawal Symptom Severity on the Marijuana Withdrawal Checklist (MWC) at 28 Days Following Single Dose Administration of Rimonabant or Placebo, or Commencement of…
N/A N=75 Development and Efficacy Test of Computerized Treatment for Marijuana Dependence
Marijuana Abuse and Dependence
Primary: Consecutive Weeks of Marijuana Abstinence — 3.55; 2.82; 0.78 consecutive weeks of abstinence — p=<0.05
Phase 2 N=130 Quetiapine Pharmacotherapy for Cannabis Dependence
Cannabis Dependence
Primary: Marijuana Use, Daily Dollar Averaged Over 7 Days During Each of 12 Weeks of Study — 14.00; 7.00; 10.00; 8.00 dollars
Phase 2 N=72 Varenicline Treatment for Cannabis Use Disorder
Substance Use Disorder
Primary: Cannabis Withdrawal Symptoms During Active Treatment — 2.23; 3.94; 2.59; 4.07 score on a scale
Phase 2 N=16 Baclofen Effects on Marijuana Dependence
Marijuana Dependence
Primary: Urine Drug Screen — 0; 0 Participants
Early Phase 1 N=30 Behavioral Effects of Pregabalin and Cannabis
Cannabis-use Disorders
Primary: Number of Self-administered Puffs of Smoked Cannabis Containing Active THC Concentrations Compared to Placebo Under Controlled Laboratory Conditions — 2.00; 2.67; 3.60…
Phase 2 N=174 UH3 Varenicline for Cannabis Use Disorder
Cannabis Use Disorder
Primary: Efficacy of Varenicline vs. Placebo for Reducing Total Number of Weekly Cannabis Use Sessions — 10.3; 11.6; 9.4; 11.7 number of weekly use sessions
Phase 2 N=133 Behavioral Economic Analysis of Demand for Marijuana
Marijuana Smoking
Primary: Validity of the Marijuana Purchase Task (MPT) — 63 percentage of participants — p=.00000004
Phase 2 N=157 Marijuana's Impact on Alcohol Motivation and Consumption
Alcohol Drinking · Marijuana
Primary: Alcohol Craving — 2.54; 2.64; 2.65; 2.55 units on a scale
Phase 2 N=38 Atomoxetine Treatment for ADHD and Marijuana Dependence
Marijuana Abuse · Attention Deficit Disorder With Hyperactivity
Primary: Estimated Week 12 Self-reported Use — 2.17; 1.84 Times per day
Phase 2 N=156 Dronabinol Treatment for Marijuana Addiction
Marijuana Abuse
Primary: Proportion of Patients Abstinent From Marijuana During Weeks 7 and 8 of the Trial — 14; 12 participants
Phase 2 N=12 Cognitive Behavioral Therapy and the Nicotine Transdermal Patch for Cannabis Dependence and Nicotine Dependence
Cannabis Dependence · Nicotine Dependence
Primary: Cigarette Use — 12.6; 2.1 cigarettes/day
Phase 2 N=61 Effectiveness Study of Dronabinol and BRENDA for the Treatment of Cannabis Withdrawal
Marijuana Dependence
Primary: Physiological Changes in Response to Cue-induced Craving. — 5.65 T value
Phase 2 N=50 Gabapentin Treatment of Cannabis Dependence
Cannabis Dependence
Primary: Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 12 — -966.00; -532.81 ng/ml — p=.029
Phase 2 N=45 Sativex and Behavioral-relapse Prevention Strategy in Cannabis Dependence
Cannabis Dependence
Primary: Tolerability — 0; 0; 0 Participants
Phase 1 N=8 Reinforcing Effects of Marijuana and Opioids
Marijuana Use · Opioid Use
Primary: Self-Administration of Drug Units Earned — 0.00; 3.83; 3.67; 0.00 Number of drug units
Phase 1 N=10 Opioid and Cannabinoid Interactions
Marijuana Usage · Opioid Use
Primary: Change in Subject-Rated Outcome - VAS Drug Liking — 3; 53.33; 58.89; 38.78 score on a scale
Phase 3 N=122 Combined Pharmacotherapy for Cannabis Dependency
Cannabis Dependence · Marijuana Dependence
Primary: 21 Days of Consecutive Abstinence as Measured by the Time-line Followback. — 18; 17 participants
N/A N=25 Impact of Reduced Cannabis Use on Functional Outcomes
Cannabis · Cannabis Use
Primary: Number of Participants Who Complete the Baseline Assessment — 18 Participants
Phase 2 N=150 Gabapentin Treatment of Cannabis Dependence
Cannabis Dependence · Cannabis Withdrawal · Cognitive Deficits
Primary: Percentage of Negative Urinary Drug Screens (UDS) for Cannabis at 12 Weeks Following Administration of Gabapentin or Placebo During the Double Blind Period — 11.22…
Phase 3 N=127 The Role of Sleep in the Treatment of Cannabis Use Disorders
Drug Addiction
Primary: Sleep Efficiency as Assessed by Percentage of Time Asleep While in Bed — 78; 74 percentage of time asleep while in bed
N/A N=269 Effect of Medical Marijuana on Neurocognition and Escalation of Use
Pain · Insomnia · Depression
Primary: Mean Difference in Number of Cannabis Use Disorder Symptoms Averaged Over 2, 4, and 12 Weeks — 0.39; 0.12 score on a scale — p=<0.001